HDAC Inhibitors Induce HLA Class I Molecules through the SOX10–IRF1 Axis in Clear Cell Sarcoma Cells
Biological and Pharmaceutical Bulletin · 2024
DOI: 10.1248/bpb.b24-00640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Minh Thi Nguyen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama. Hauptthemen laut MEDLINE: Interferon Regulatory Factor-1, Histone Deacetylase Inhibitors, SOXE Transcription Factors, Sarcoma, Clear Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Although immune checkpoint inhibitors (ICIs) are an effective treatment for clear cell sarcoma (CCS), a rare melanocytic sarcoma with a poor prognosis, their efficacies are still limited. Therefore, a novel therapeutic strategy is required to improve the efficacy of ICIs. We previously reported that histone deacetylase (HDAC) inhibitors increased melanoma immunogenicity through the SOX10-IRF1 pathway and may improve the efficacy of ICIs for melanoma. We herein demonstrated that the inhibition of HDAC induced the expression of HLA class I molecules through IRF1 in CCS cells, similar to melanoma. The suppression of SOX10 by small interfering RNA (siRNA) induced the expression of HLA class I molecules. In addition, the isoform-specific inhibition of HDAC1/3 induced the expression of another IRF1 downstream molecule, PD-L1 in CCS cells in concert with the suppression of SOX10. Furthermore, the knockdown of IRF1 impaired the induction of PD-L1 expression in CCS cells. Therefore, the inhibition of HDAC1/3 has potential as a novel strategy to increase immunogenicity and as combination therapy with ICIs for CCS and melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama.
- Department of Medical Oncology, Toyama University Hospital.
- Division of Pediatrics, Faculty of Medicine, University of Miyazaki.
- Department of Experimental Pathology, Institute of Medical Science, Tokyo Medical University.
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine.
Zitieren
APA
Nguyen, M. T., Kikuchi, R., Nishibu, S., Zhou, Y., Moritake, H., Nakamura, T., Outani, H., Hayashi, R., Sakurai, H., & Yokoyama, S. (2024). HDAC Inhibitors Induce HLA Class I Molecules through the SOX10–IRF1 Axis in Clear Cell Sarcoma Cells. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00640
Vancouver
Nguyen MT, Kikuchi R, Nishibu S, Zhou Y, Moritake H, Nakamura T, et al. HDAC Inhibitors Induce HLA Class I Molecules through the SOX10–IRF1 Axis in Clear Cell Sarcoma Cells. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00640
BibTeX
@article{Nguyen2024,
author = {Nguyen, Minh Thi and Kikuchi, Ryota and Nishibu, Soshi and Zhou, Yue and Moritake, Hiroshi and Nakamura, Takuro and Outani, Hidetatsu and Hayashi, Ryuji and Sakurai, Hiroaki and Yokoyama, Satoru},
title = {HDAC Inhibitors Induce HLA Class I Molecules through the SOX10–IRF1 Axis in Clear Cell Sarcoma Cells},
journal = {Biological and Pharmaceutical Bulletin},
year = {2024},
doi = {10.1248/bpb.b24-00640}
}
EUVIMED